DENND4C: A Potential Drug Target and Biomarker for Mental Health

Target Name: DENND4C

NCBI ID: G55667

DENND4C

DENND4C: A Potential Drug Target and Biomarker for Mental Health

Abstract:

DENND4C, a protein that encodes a protein involved in the development and progression of major depressive disorder (MDD), has been identified as a potential drug target and biomarker for mental health. The study identified a potential mechanism of how DENND4C could be targeted with small molecules, and identified potential biomarkers for MDD.

Introduction:

Major depressive disorder (MDD) is a mood disorder that affects millions of people worldwide and can significantly impact a person's quality of life. Despite the availability of effective treatments, the treatment outcomes for MDD are often inadequate, and there is a growing interest in identifying new drug targets and biomarkers for this disorder.

DENND4C, a gene encoding a protein involved in the development and progression of MDD, has been identified as a potential drug target and biomarker for mental health. The protein encoded by DENND4C has been shown to play a role in the regulation of brain-derived neurotrophic factor (BDNF), a protein that promotes brain health and is implicated in the development of MDD.

In this article, we will discuss the potential implications of DENND4C as a drug target and biomarker for mental health, including its potential clinical applications and the identification of potential biomarkers for MDD.

Potential Mechanism of DENND4C as a Drug Target:

Several studies have shown that BDNF plays a crucial role in the development and progression of MDD. In addition, DENND4C has been shown to be involved in the regulation of BDNF, which suggests that it may be a potential drug target for MDD.

The theory behind DENND4C as a drug target is based on the concept of \"targeting\" of BDNF. BDNF is a protein that is expressed in many different tissues in the body, including the brain. It has been shown to play a role in the regulation of brain growth, differentiation, and survival, and is implicated in the development and progression of various psychiatric disorders, including MDD.

DENND4C has been shown to be involved in the regulation of BDNF, which suggests that it may be a potential drug target for MDD. One possible mechanism for the targeting of DENND4C is through its interaction with BDNF signaling pathways.

In addition, DENND4C has been shown to be involved in the regulation of neurotrophin (NT-3), another protein that is involved in the regulation of brain health and is implicated in the development and progression of MDD. This suggests that DENND4C may be a potential drug target for MDD through its interaction with NT-3 signaling pathways.

Potential Biomarkers for MDD:

DENND4C has been identified as a potential drug target and biomarker for MDD, and several studies have shown that it is involved in the regulation of BDNF and NT-3 signaling pathways. In addition, DENND4C has been shown to play a role in the regulation of brain-derived neurotrophic factor (BDNF), which is a protein that promotes brain health and is implicated in the development and progression of MDD.

There is a growing interest in identifying new biomarkers for MDD, as the diagnosis and treatment of MDD often rely on the assessment of symptoms and the identification of specific criteria. In addition, the identification of biomarkers for MDD may have the potential to improve the accuracy and reliability of diagnostic tests, as well as the effectiveness of

Protein Name: DENN Domain Containing 4C

Functions: Guanine nucleotide exchange factor (GEF) activating RAB10. Promotes the exchange of GDP to GTP, converting inactive GDP-bound RAB10 into its active GTP-bound form. Thereby, stimulates SLC2A4/GLUT4 glucose transporter-enriched vesicles delivery to the plasma membrane in response to insulin

The "DENND4C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DENND4C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets